These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36599470)

  • 1. T lymphocytes induce human cancer cells derived from solid malignant tumors to secrete galectin-9 which facilitates immunosuppression in cooperation with other immune checkpoint proteins.
    Schlichtner S; Yasinska IM; Lall GS; Berger SM; Ruggiero S; Cholewa D; Aliu N; Gibbs BF; Fasler-Kan E; Sumbayev VV
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36599470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Tim-3-Galectin-9 Pathway and Its Regulatory Mechanisms in Human Breast Cancer.
    Yasinska IM; Sakhnevych SS; Pavlova L; Teo Hansen Selnø A; Teuscher Abeleira AM; Benlaouer O; Gonçalves Silva I; Mosimann M; Varani L; Bardelli M; Hussain R; Siligardi G; Cholewa D; Berger SM; Gibbs BF; Ushkaryov YA; Fasler-Kan E; Klenova E; Sumbayev VV
    Front Immunol; 2019; 10():1594. PubMed ID: 31354733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligand-Receptor Interactions of Galectin-9 and VISTA Suppress Human T Lymphocyte Cytotoxic Activity.
    Yasinska IM; Meyer NH; Schlichtner S; Hussain R; Siligardi G; Casely-Hayford M; Fiedler W; Wellbrock J; Desmet C; Calzolai L; Varani L; Berger SM; Raap U; Gibbs BF; Fasler-Kan E; Sumbayev VV
    Front Immunol; 2020; 11():580557. PubMed ID: 33329552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional role of galectin-9 in directing human innate immune reactions to Gram-negative bacteria and T cell apoptosis.
    Schlichtner S; Meyer NH; Yasinska IM; Aliu N; Berger SM; Gibbs BF; Fasler-Kan E; Sumbayev VV
    Int Immunopharmacol; 2021 Nov; 100():108155. PubMed ID: 34543981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of the Immune Checkpoint Protein VISTA Is Differentially Regulated by the TGF-β1 - Smad3 Signaling Pathway in Rapidly Proliferating Human Cells and T Lymphocytes.
    Schlichtner S; Yasinska IM; Ruggiero S; Berger SM; Aliu N; Prunk M; Kos J; Meyer NH; Gibbs BF; Fasler-Kan E; Sumbayev VV
    Front Med (Lausanne); 2022; 9():790995. PubMed ID: 35223897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of Galectin-9 Treatment on the Phenotype and Function of NK-92MI Cells in the Presence of Different Serum Supplements.
    Meggyes M; Nagy DU; Balassa T; Godony K; Peterfalvi A; Szereday L; Polgar B
    Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
    Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
    J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Transfusion Promoted Reprogramming CD4
    Zhang L; Zhang JP; Liu Y; Wang H; Cheng Y; Wang JH; Zhang WJ; Li ZZ; Guo JR
    Cell Transplant; 2020; 29():963689720947347. PubMed ID: 32907380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors.
    Komita H; Koido S; Hayashi K; Kan S; Ito M; Kamata Y; Suzuki M; Homma S
    Oncol Rep; 2015 Oct; 34(4):2099-105. PubMed ID: 26239720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins.
    Sioud M; Mobergslien A; Boudabous A; Fløisand Y
    Int J Oncol; 2011 Feb; 38(2):385-90. PubMed ID: 21165555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galectin-3 Released by Pancreatic Ductal Adenocarcinoma Suppresses γδ T Cell Proliferation but Not Their Cytotoxicity.
    Gonnermann D; Oberg HH; Lettau M; Peipp M; Bauerschlag D; Sebens S; Kabelitz D; Wesch D
    Front Immunol; 2020; 11():1328. PubMed ID: 32695112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transforming growth factor beta type 1 (TGF-β) and hypoxia-inducible factor 1 (HIF-1) transcription complex as master regulators of the immunosuppressive protein galectin-9 expression in human cancer and embryonic cells.
    Selnø ATH; Schlichtner S; Yasinska IM; Sakhnevych SS; Fiedler W; Wellbrock J; Klenova E; Pavlova L; Gibbs BF; Degen M; Schnyder I; Aliu N; Berger SM; Fasler-Kan E; Sumbayev VV
    Aging (Albany NY); 2020 Dec; 12(23):23478-23496. PubMed ID: 33295886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of Galectin-9/TIM-3 pathway in the systemic inflammatory response in early-onset preeclampsia.
    Miko E; Meggyes M; Bogar B; Schmitz N; Barakonyi A; Varnagy A; Farkas B; Tamas P; Bodis J; Szekeres-Bartho J; Illes Z; Szereday L
    PLoS One; 2013; 8(8):e71811. PubMed ID: 23936526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels.
    Seifert AM; Reiche C; Heiduk M; Tannert A; Meinecke AC; Baier S; von Renesse J; Kahlert C; Distler M; Welsch T; Reissfelder C; Aust DE; Miller G; Weitz J; Seifert L
    Oncogene; 2020 Apr; 39(15):3102-3113. PubMed ID: 32055023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galectin-3 is modulated in pancreatic cancer cells under hypoxia and nutrient deprivation.
    da Silva Filho AF; Tavares LB; Pitta MGR; Beltrão EIC; Rêgo MJBM
    Biol Chem; 2020 Sep; 401(10):1153-1165. PubMed ID: 32755098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Varied expression and localization of multiple galectins in different cancer cell lines.
    Satelli A; Rao PS; Gupta PK; Lockman PR; Srivenugopal KS; Rao US
    Oncol Rep; 2008 Mar; 19(3):587-94. PubMed ID: 18288388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VISTA expression and patient selection for immune-based anticancer therapy.
    Martin AS; Molloy M; Ugolkov A; von Roemeling RW; Noelle RJ; Lewis LD; Johnson M; Radvanyi L; Martell RE
    Front Immunol; 2023; 14():1086102. PubMed ID: 36891296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and characterization of anti-galectin-9 antibodies that protect T cells from galectin-9-induced cell death.
    Yang R; Sun L; Li CF; Wang YH; Xia W; Liu B; Chu YY; Bover L; Vien L; Hung MC
    J Biol Chem; 2022 Apr; 298(4):101821. PubMed ID: 35283189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
    Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
    IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.
    Lahm H; André S; Hoeflich A; Fischer JR; Sordat B; Kaltner H; Wolf E; Gabius HJ
    J Cancer Res Clin Oncol; 2001; 127(6):375-86. PubMed ID: 11414198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.